Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Sells $278,196.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Neena Patil sold 1,200 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $5.61 on Friday, reaching $230.56. 635,707 shares of the company’s stock were exchanged, compared to its average volume of 993,192. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32. The business’s 50-day moving average is $216.77 and its two-hundred day moving average is $188.55. The firm has a market capitalization of $14.48 billion, a price-to-earnings ratio of -11,522.24, a PEG ratio of 0.21 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion for the quarter. As a group, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 132.6% in the 1st quarter. NewEdge Advisors LLC now owns 1,975 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 1,126 shares in the last quarter. Glenmede Trust Co. NA raised its holdings in Jazz Pharmaceuticals by 1.9% during the 1st quarter. Glenmede Trust Co. NA now owns 7,819 shares of the specialty pharmaceutical company’s stock worth $1,478,000 after purchasing an additional 146 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Jazz Pharmaceuticals by 10.9% in the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after acquiring an additional 99,656 shares during the last quarter. Tri Locum Partners LP bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $29,995,000. Finally, Amundi increased its stake in shares of Jazz Pharmaceuticals by 2,445.3% in the 1st quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock valued at $10,519,000 after acquiring an additional 53,454 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JAZZ shares. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $188.00 to $307.00 in a research report on Tuesday, May 19th. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday. Bank of America raised their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler lifted their price target on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, May 22nd. Finally, Leerink Partners raised their price objective on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $246.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.